GlassScriptPhysician profile
Paul Gennaro
NPI 1942268412
$3,743.67
in general payments reported to CMS, 2019-2025
42 companies · $18.06 in 2025
The $18.06 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $322 · 2021: $450 · 2022: $725 · 2023: $1,101 · 2025: $18.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $601.59 | 2019-2023 | |
| Ucb, INC. | $438.31 | 2019-2023 | Briviact |
| Abbvie INC. | $285.35 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $220.86 | 2019-2023 | Xywav |
| Biogen, INC. | $211.79 | 2019-2023 | Vumerity, Tysabri |
| Pfizer INC. | $153.01 | 2023 | |
| Eisai INC. | $147.78 | 2019-2023 | |
| Greenwich Biosciences, INC. | $137.50 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.45 | 2022 | |
| Argenx US, INC. | $117.29 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $102.31 | 2019-2023 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $99.02 | 2019-2023 | Austedo |
| Amneal Pharmaceuticals LLC | $98.66 | 2020-2023 | Rytary |
| Amgen INC. | $88.28 | 2019-2022 | |
| Tanabe Pharma America, INC. | $86.96 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gennaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.